A phase 1b/2 study of safety and efficacy of MLN0128 (Du

Project: Research project

Project Details

Description

A phase 1b/2 study of safety and efficacy of MLN0128 (Dual TORC 1/2 Inhibitor) in combination withexemestane or fulvestrant therapy in postmenopausal women with ER+/HER2- advanced or metastatic breast cancer
StatusActive
Effective start/end date5/1/145/30/21

Funding

  • MILLENNIUM PHARMACEUTICALS, INC.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.